Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Lee CK, et al. Among authors: jang js. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY. Lee J, et al. Among authors: jang js. Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20. Lancet Oncol. 2012. PMID: 22192731 Clinical Trial.
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ. Jang JS, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. doi: 10.1007/s00280-009-1069-7. Epub 2009 Aug 4. Cancer Chemother Pharmacol. 2010. PMID: 19652971 Clinical Trial.
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Jung HA, Hong MH, Lee HW, Lee KH, Kim IH, Min YJ, Ahn HK, Shim BY, Choi YH, Lee YG, Kim JA, Jang JS, Shin SH, Park KU, Kang JH, Park K. Jung HA, et al. Among authors: jang js. Transl Lung Cancer Res. 2022 Jul;11(7):1369-1379. doi: 10.21037/tlcr-22-79. Transl Lung Cancer Res. 2022. PMID: 35958320 Free PMC article.
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, Kim BS, Kang JH, Lee KH, Kim SW, Ryoo HM, Kim JS, Lee KH, Kwon JH, Choi JH, Shin SW, Hahn S, Heo DS. Kim DW, et al. Among authors: jang js. Cancer Res Treat. 2019 Jan;51(1):119-127. doi: 10.4143/crt.2018.019. Epub 2018 Mar 12. Cancer Res Treat. 2019. PMID: 29529858 Free PMC article. Clinical Trial.
784 results